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Abstract
The sphingolipid ceramide exerts a pro-apoptotic role in variety of cellular and
organ systems and increased of de-novo synthesis of ceramide are associated
with initiation of cell death. In Retinitis Pigmentosa (RP) photoreceptor death
occurs by apoptosis but the individual pathways of this process are unknown.
We employed an animal model of RP, the rd10 mutant mouse, to assess the
role of ceramide in inherited photoreceptor degeneration. We used Myriocin, a
known inhibitor of serine palmitoyltransferase (SPT, the rate-limiting enzyme
of ceramide biosynthesis) which was either injected intravitreally in a single
dose or administered daily to rd10 mice as eye drops of Solid Lipid Nanoparti-
cles (SLNs). Control mice were given intravitreal injections of vehicle alone or
unloaded lipid particles, respectively. We found that retinal ceramide levels in
rd10 mice double from P14 to P30, the time interval of maximum photoreceptor
death in this strain. Intraocular treatment with Myriocin decreases the number
of pycnotic photoreceptors in rd10 mice by approximately 50%. Electroretino-
gram (ERG) recordings were obtained from animals of various ages chronically
treated with Myriocin-SLNs. ERG a-waves persist after P30 in treated mice
while these responses are virtually extinct in control littermates. Retinal sec-
tions from ERG recorded animals were examined at a confocal microscope to
estimate photoreceptor survival. Morphometric analysis of retinas from rd10
mice aged P24 (peak of rod apoptosis) up to P30 showed prolonged survival of
photoreceptors in treated animals. This study demonstrates in a mammalian
model of RP that it is possible to decrease the rate of apoptotic death of pho-
toreceptors in vivo by lowering retinal ceramide levels through inhibition of the
de-novo biosynthesis of this molecule. Non-invasive, chronic administrations of
nanoparticles loaded with SPT inhibitors are effective in prolonging survival
and light responsiveness of photoreceptors.
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Chapter 1
Introduction
1.1 Retina
Vision is very important in humans because the eye is dedicated to capture
light reflected by the scene surronding the subject, to encode it into electrical
signals and efficiently transfer them to the brain. A cross-sectional view of the
eye shows three different layers:
1. The external layer, formed by the sclera and cornea
2. The intermediate layer, divided into two parts: anterior composed by iris
and ciliary body and posterior
3. The internal layer that represents the sensory part of the eye, the retina.
1.1.1 Morphological structure of the retina
Surrounding the fovea there is a circular area of approximately 6mm in diameter
called central retina while beyond this is peripheral retina stretching to the ora
serrata that represents the center of the optic nerve. A redial section of the retina
shows that the ganglion cells (the output neurons of the retina) lie innermost
in the retina closest to the lens and front of the eye, and the photoreceptors
(rods and cones) lie outermost in the retina against the pigment epithelium and
choroid. A vertical section of the retina is as follows:
• Pigmented Epithelium (PE): placed at the periphery of the retina, is the
pigmented cell layer just outside the neurosensory retina that nourishes
retinal visual cells, and is firmly attached to the underlying choroid and
overlying retinal visual cells. the PE is involved in the phagocytosis of the
outer segment of photoreceptors cells and it is also involved in the vitamin
A cycle where it isomerizes all trans retinol to 11-cis retinal. PE also serves
as the limiting transport factor that maintains the retinal environment by
supplying small molecules such as amino acid, ascorbic acid and D-glucose
while remaining a tight barrier to choroidal blood borne substances. The
ionic enviroment is maintained by a particular exchange system.
• Photoreceptors Layers: contain both Outer and Inner Segment (OS/IS) of
the photoreceptors. The OS is the most distal part of photoreceptors and
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in this location a multi-stage processe known as phototrasduction begins
with light-induced isomerization of a pigment (rhodopsin or cone-opsin).
The whole photodrasductive machinery is contained in here. The IS is
connected to the OS by a thin cilium, it is the portion of the photoreceptors
where most of the biosynthetic processes take place.
• Outer Nuclear Layer (ONL): Contain all the photoreceptors nuclei and
the terminal processes of Muller glia.
• Outer Plexiform Layer (OPL): Layer where are synaptical contact between
photoreceptors and bipolar cells (second-order neurons).
• Inner Nuclear Layer (INL): Contain the cellular bodies of the all second-
order neurons (rod- and cone-bipolar cells, amacrine cells, horizontal cells)
and of the non-neural Muller glia.
• Inner Plexiform Layer (IPL): In this layer there are the synaptical contact
between second-order neurons and ganglion cells.
• Ganglion Cell Layer (GCL): Contain both ganglion cell and displaced
amacrine cellular bodies. Ganglion cells represent the third-order neu-
rons, the only neurons generating both spontaneus and light-evoked spike
potentials.
• Optic Nerve Fiber Layer (NFL): It’s the output of the axon of the ganglion
cells to the brain. Packed together they form the optic nerve and at the
level of optic disc assumes the usual myelination.
1.1.2 Retina of the Mouse vs Human
In the mouse retina we can recognise the same layer of the human retina. The
mouse retina is rod-dominated (rods 4.5milion versus cones 125.000) and at
variance with human retina there aren’t three type of cones but only two: green
and blu cones. Similarly to those of humans, photoreceptors of the rodents, rods
and cones, absorb photons and convert them into electrical signals. Dim light
signals have sufficient energy to excite the rods, while cones are less sensitive
and to be excited require much brighter lights. Therefore rod photoreceptor
cells operate in the twilight while cone visual cells are active at daylight and
subserve color vision. Photoreceptor cells may be connected to the neighbor-
ing cells by electrical synapses (gap junctions) and establish chemical synapses
with bipolar and horizontal cells. Bipolar cells are subdivided into two main
classes: rod and cone bipolar, each bipolar cells make contact with the corre-
sponding photoreceptor populations. Cone bipolar cells are furhter divided in
two subtype: ON- and OFF-bipolar cells, that respectively depolarize and hy-
perpolarize in response to the illumination of their receptive field centers. All
rod-bipolar cells are of subtype ON and establish direct connection with ON
ganglion cells (RGC) through amacrine cells. Both ON- and OFF cone-bipolar
cells are connected directly to respectively ON or OFF RGCs.
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Figure 1.1: Morphological representation of the retina in a vertical section of
the adult human eye. Retinal layers on the left. Principal neuronal classes on
the right. RBC: rod bipolar cell, HC: horizontal cell, CBC: cone bipolar cell,
AC: amacrine cell, GC: ganglion cell
1.2 Retinal Degenerations (RDs)
A very high number of genetic mutations affect the eye and a large number of
mutations affect photoreceptors or pigment epithelium and may cause retinal
degeneration (RDs). Retinitis Pigmentosa (RP) comprises a group of hetero-
geneus genetic disorders that cause severe loss of vision in as many as 1.5 milion
individuals worldwide (review: [68], [44],[81]). The mutation mainly affects the
rod photoreceptors which mediate the scotopic vision (dim light conditions).
When rods start to die, in response to genetic abnormality, symptoms appear
and the night vision of patients is reduced and the visual field is constricted
(tunnel vision). RP usually follows a two-stage process in which first the rod-
photoreceptors degenerate, then also cone-photoreceptors start to die resulting
in the loss of central vision. At this stage of RP also blood vassel distrophy and
intraretinal brown pigment accumulation occur. It is unusual for patients with
RP to became totally blind as most of them retain some useful vision well into
old ages. Type of RP and related diseases include, among others, Usher syn-
drome, Leber’s congenital amaurosis, rod-cone disease, Bardet-Biedl syndrome
and Refsum disease.
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Figure 1.2: The progressive die of the rod-photoreceptors lead to loss of periph-
eral vision.
Figure 1.3: A typical brown pigmentation is present in the pathological condi-
tion. Pigment deposits, named bone spicules for their shape, are responsiblefor
the name of the disease. In these image is also visible a clear attenuation of
retinal blood vassels.
1.2.1 Retinitis Pigmentosa: Genetics and Molecular Mech-
anisms
There are three principal types of RP: autosominal dominant (ad), autosominal
recessive (ar) and X-linked. RP causing mutations have been identified in more
than 35 genes. Genetic mutations (as deletions, insertions, or substitutions)
triggering potoreceptors degeneration and then death by apoptosis, often affect
the retinoid acid cycle or the phototransduction cascade. Phototransduction
starts with a light-induced, conformational change of 11-cis-retinal to all-trans-
retinal. This in turn activates opsin molecules, causing sequential activation of
transducine and cyclic guanosine monophosphate (cGMP)-phosphodiesterase-6
(PDE6) and subsequent decreases in intracellular cGMP concentration. High
cGMP levels maintain cyclic nucleotide-gated (CNG) cation channels in the
open state, allowing the influx of cations including sodium and calcium. Reduc-
tion of cGMP levels closes CNG channels causing cell hyperpolarization. This
signal is then transmitted to second order neurons in the INL Fig.1.4 ([68]).
There are mainly two mutations affecting the phototransductive process: the
first concerns, the Rhodopsin gene (RHO), this is the best studied mutation
and is responsible for varius forms of autosominal dominant RP (adRP); the
second, that affects the phosphodiesterase gene (Pdeb), leads to autosominal
recessive RP (arRP) and this is the defect carried by the mouse models used in
the present study (explained in more detail later).
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Figure 1.4: Pathway of the visual transduction cascade.
1.2.2 RHO Mutations
Rhodopsin is a prototypic member of the G-protein-coupled receptor family and
its molecular structure has been known for some time ([79],[80]). The visual pig-
ment molecule consists of a protein component (a 348 amino acid sequence orga-
nized into three distinct domains: cytoplasmic, transmembrane and intradiscal),
and chromophore group (11-cis-retinal a light absorbing polyen structure where
phototransduction initiates, fig.1.4) The most common mutation in RHO gene
is the change of proline to histidine at codon 23 (P23H), this mutation leads to
a phenotype classified as class B1 with a typical features that includes slower
progression and better visual function compared to other forms of adRP. Be-
sides P23H, there are several other types of mutations in the RHO gene that
are classified as follows:
• Class I: mutations basically occur in the C-terminus of the protein, this
part of the protein is important for its translocation to the plasma mem-
brane and could form a functional chromophore with 11-cis-retinal.
• Class II: the most common adRP mutations, were characterized by muta-
tions in the intradiscal membranes and cytoplasmatic domain of rhodopsin,
which resulting in misfolding of the protein, defined by the inability to
form a functional chromophore with 11-cis-retinal.
• Class III: corresponds to mutations that affect endocytosis (R135L muta-
tion).
• Class IV: these mutations affect the rhodopsin stability and post - trans-
lational modification, such as T4R mutation that causes adRP in dogs.
• Class V: have no abvius initial folding defect but show an increased acti-
vation rate of for transducin.
• Class VI: this mutant appears to fold correctly bat leads to the constitutive
activation of opsin in the absence of chromophore and in dark.
Dominance in adRP patients could be due to loss-of-function, gain-of-function
or dominant-negative mutations, or any of the above in combination.
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Several animal models of rhodopsin-associated RP have been generated and in-
clude the rhodopsin knockout mouse lacking any functional rhodopsin and thus
rapidly undergoes retinal degeneration, and dominant transgenic models such
as the P23H mouse ([77]). These animals are an extremely valuable resource in
the study of rhodopsin-induced degeneration mechanisms.
1.2.3 Mutations in photoreceptor structural proteins
Several of the known RP genes encode proteins that have pivotal roles in the
formation and maintenance of the highly complex and delicate cellular struc-
ture of the rod (Fig.1.5). Peripherina 2 also known as retinal degeneration slow
Figure 1.5: This figure show a schematic representation of the complex photore-
ceptor strcture.
(RDS), a transmembrane glycoprotein, is one of the earliest proteins to be asso-
ciated with RP. Mutations in RDS lead to several different retinal phenotypes
including arRP, cone-rod dystrophy and adRP
(http://www.sph.uth.tmc.edu/Retnet/home.htm).
RDS estabilishes complexes that have an integral role in the morphogenesis and
structure of the stacked discs in both rod and cone OS (see fig.1.5). RDS mu-
tations lead to RP by two different mechanisms. First, alterations prevent the
protein from forming tetramers, inhibiting its transportation from the transla-
tion site in the IS to the OS; second, the mutant protein is incorporated into
the nascent disc but causes them to be inherently unstable and RP develops be-
cause of the disorganization that ensues in the OS ([26],[42], [57]). Mutations in
the RP1 gene are among the most common causes of adRP and are responsible
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for 6-10 per cent of cases. The role of the RP1 protein might be central to the
morphogenesis of the photoreceptors OS ([107]).
1.2.4 Abnormalities in retinal transcriptional factors
The process that occurs in development, differentiation and maintenance of the
photoreceptors are under the control of several transcription factors, such as
cone-rod homeobox-cointaining (CRX) and neural retina leucine zipper (NRL)
genes. CRX is essential for photoreceptor development and when mutated is
associated with the early onset retinal degeneration laber congenital amaurosis
(LCA) and adRP; NRL is pivotal in the determination and development of
the photoreceptors and also in their function and maintenance in the adult, in
patients with NRL mutations, it appears that the detrimental effects might be a
result of increased expression of rhodopsin and other photoreceptor gene ([17]).
1.2.5 Rod-phosphodiesterase (PDE) gene mutations
Several forms of the arRP are caused by mutations carried in the PDE gene.
Cyclic GMP-phosphodiesterase is composed of four subunits, two with catalytic
activity, α and β, and two identical gamma subunits with inhibitory activity.
This enzyme is fundamentally important for phototrasduction in photoreceptors
([25]).
cGMP phosphodiesterase type 6 (PDE6) is the specific enzyme in rod-photoreceptor.
PDE6 is activated in response to light stimulation of the receptor in the outer
segments of rod (Fig.1.4). A visual cascade of biochemical reactions is initiated
when rhodopsin is activated by the incident light. Activated rhodopsin stim-
ulates the exchange of GDP for GTP and activates the G-protein, transducin.
Transducin activates PDE6 by displacing the inhibitory γ-subunits from the
active site of the enzyme, thereby greatly stimulating cGMP hydrolysis. PDE6
rapidly reduces the cytoplasmic cGMP concentration, which causes closure of
cGMP-gated channels and produces a transient hyperpolarization of the rod
plasma membrane leading to a reduction in glutamate release at the synapse
([40]).
In 1924 Keeler and collaborators discovered for the first time the mutations in
the PDE gene in rodless mice (r) ([43]), this were a nonsense mutation in the
PDE gene coding for the beta-subunit of cGMP phosphodiesterase gene.This
spontaneus mutation was later rediscovered in the retinal degeneration mouse
(rd1 or rd)([9],[84], [85], [86]) and subsequently in humans with arRP and adRP
form of night blindness ([66], [65], [28]).
Mouse model of retinal degeneration has been investigated for many years in the
hope of understanding the causes of photoreceptors cell death. The first retinal
degeneration observed is rd1. This mutation has been found among several com-
mon laboratory strain (such as C3H and CBA/J) and mice homozygous for the
rd1 mutation have an early onset severe retinal degeneration due to a murine
viral insert (MLV) and a second nonsense mutation in exon 7 of the Pde6b gene
enconding the beta subunit of cGMP-PDE. Mice with the rd1 mutation can be
easily typed by phenotype based on vassel attenuation and pigment patches in
the fundus (Fig.1.6) ([14]).
Biochemical studies comparing retinas from wt and rd1 mice have shown that
the lack of cGMP-PDE activity causes a dramatic increase in cytoplasmatic
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Figure 1.6: This image show the appearance of the ocular fundus in the rd1
mice retina.
cGMP concentration, this, in turn, leads to a permanent opening of the cGMP
gated cation channels on the photoreceptor membrane with an increase of the
extracellular ions influx, particularly Ca2+. It has been suggested that this
increase in intracellular Ca2+ causes a metabolic overload of the cells, eventu-
ally leading to cell death by apoptosis ([16]). Excessive Ca2+ influx has long
been regarded as a major factor in photoreceptor degeneration and strong ac-
tivation of Ca2+-dependent enzymes has been observed in rd1 photoreceptors.
Certainly, Ca2+ is seen as a trigger of apoptosis through the inactivation of
mitochondria and subsequent activation of apoptotic machinery. On the other
hand, Ca2+ influx causes ATP depletion by activating Ca2+ extrusion mecha-
nisms such as Ca2+-ATPaese or the Na-ATPases required to drive Na+/Ca2+
exchangers, while at the same time inhibiting mitochondrial ATP synthesis. A
possibility is that the observed rise in retinal Ca2+ levels is only secondary to
the degeneration process and it is not even clear whether it occurs in photore-
ceptors or in other retinal cell types. Furthermore, fluctuations in cytosolic
Ca2+ may be caused not only by Ca2+ influx from extracellular sources bat
also by intracellular release from the mitochondria, photoreceptor discs or the
endoplasmatic reticulum (ER). Further, other mechanisms can lead to cell death
such as oxdative stress and activation of the proapoptotic protein. In summary
Ca2+, the energetic status, and ER stress are different factors that appear to be
interconnected in cell death: a primary rise in intracellular Ca2+ triggered by
ER stress could be followed by mitochondrial dysfunction, an energetic collapse,
and a secondary wave of extracellular Ca2+ ([90]).
In addition to rd1 mouse model, other naturally occuring mouse mutants that
manifest degeneration of photoreceptors in the retina with preservation of all
other retinal cell types have been found such as:
• Purkinje cell degeneration (pcd)
• nervous (nr)
• retinal degeneration slow (rds)
• motor neuron degeneration (mnd)
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• vitiligo (vit)
• neuronal ceroid lipofuscinosis (nclf )
• cone photoreceptor function loss (cpfl1 )
• and several types of retinal degeneration (rd3, rd4, rd5, rd6, rd7, rd8, rd9
and rd10 ) ([14]).
1.2.6 The rd10 mutant mouse
Retinal degeneration 10 (rd10 ) mouse is a viable model of human retinitis pig-
mentosa and this strain is used in the present study. Genetic analysis shows that
these mice carry an autosomal recessive mutation that maps into chromosome
(Chr) 5. Sequence analysis shows that the retinal degeneration is caused by a
missense point mutation in 13th exon in the Pde6b gene of the beta-subunit of
the rod cGMP phosphodiesterase (beta-PDE). The mutation changes codon 560
from CGC to TGC resulting into an arginine to a cysteine. The exon 13 mis-
sense mutation is the first known occurence of a remutation in the Pde6b gene in
mice and provide a good model for studying the pathogenesis of arRP in human.
It also provides a better model than rd1 for experimental pharmaceutical-based
therapy for RP because of its later onset, slowly progressing and less severe
retinal degeneration compared to that affecting the rd1 ([14]).
In the rd10 mice the number of photoreceptor rows is 12-14 at postnatal day
10 (P10) and 11-12 rows at P20. From P20 to P25 there is a substantial re-
duction in the number of photoreceptor rows and at P30 cones are shortened
outer and inner segmented and a deformed shape. At P45, only a single row
of photoreceptors is present (Fig.1.7). Degeneration of photoreceptors in rd10
retinas follows a center-to-periphery gradient: the decrease in the number of
ONL rows becomes apparent in the central retina first, whereas degeneration
in the periphery is delayed ([29]). Atrophic retinal vessels are found at four
weeks of age, consistent with retinal degeneration ([15], [29]). After extensive
photoreceptor death, dendrites of the bipolar cells exhibit a retraction. Survival
of rod bipolar and horizontal cells drops right after the peak of photoreceptor
degeneration and decreases slowly over the following months. After that, also
the INL disorganizes and typical rosettes appear.
The morphological changes have a physiological correlate. Infact elettroretino-
gram (ERG) analysis shows differences between the flash ERG of wt and rd10
mice related with severe damage affecting the distal rod pathway. The loss of
functioning rods that occurs in the rd10 mutants between P20 and P30 largely
contributes to the drastic reduction in the normalized maximal a-wave that
is directly proportional to the suppression of the dark current by light ([10]).
Note that alterations in the shape and relative amplitude of the b-wave are de-
tected as early as P18 when no morphological modification occur in inner retina.
Changes in the efficiency of the synaptic communication of rod-to-rod bipolar
cells could explain the alterations found in the ERG by using sinusoidal stimuli.
In fact the ERG mesurements obtained by using sinusoidal modulation of the
mean luminance confirm the results of the flash ERG, and provide an indication
that, even at earliest stage of the degenerative process, bipolar neurons show
signs of damage ([29]).
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1.2.7 Secondary cell death of Cone-photoreceptors
Photoreceptor degeneration results in vision loss in diseases like RP and age-
related macular degeneration. In these diseases, the main cause of clinically
significant vision loss is cone cell degeneration rather than rod cell death. In
fact most mutations responsible for RP in humans and animal models affect
rod-photoreceptor-specific genes, rod apoptosis is often followed by secondary
cone degeneration ([71]). Several possible causes have been indicated to explain
mutation-indipendent secondary cell death of cone-photoreceptors. These in-
clude loss of structural support and/or loss of trophic support, i.e, Rod-derived
Cone Viability Factor (RdCVF) ([89]) when rod negatively affect the cells are
degenerating and death. In fact, intraocular injections of this factor may to
rescue cone photoreceptors ([112]).
Another hypothesis concerning the changes in oxigen consumption levels as a
function of rod degeneration: depletion of the photoreceptor population (mainly
rods) by any cause would reduce consumption of oxygen flowing from the
choroidal circulation. Because this flow of oxygen is unregulated, photoreceptor
depletion will cause a chronic increase in oxygen tension in the outer retina, and
this increase is toxic to surviving photoreceptor (both rods and cones) ([18]).
The vulnerability of photoreceptors to hyperoxia has also been confirmed, and
evidence has been reported that rod loss results in oxidative stress to cones
([94]).
Two other hypothesis have recently been developed concerning the secondary
death of cones: rods may release toxic substances that negatively affect the
neighboring cells and a chronic activation of microglial cells has been described
in animal models of RP. It is possible that an immune response might enhance
degenerative processes and could in part be responsible for the secondary loss
of cone-photoreceptors which are not affected by the primary genetic mutation
([113]).
1.3 RP experimental therapeutic strategies
1.3.1 Transplants
The possibility of retinal transplantation represents a hope for the restoration of
vision through cell-replacement therapy. However, getting the transplanted cells
to establish the right connections within the retina has been a major problem
by far. It appears that an early developmental stage of the retina of acceptors
represents a key feature of a successful transplant. Despite decades of exper-
imental attempts, transplants have yet to produce better vision in mammals
with retinal degeneration because the transplanted cells do not wire up prop-
erly. The first successful transplant of a mammalian retina dates back to 1959,
when Royo and Quay transplanted fetal rat retinas into the eyes of adults of the
same strain. Transplants appear to develop many characteristics of a normal
retina ([93]; [115]) and grow to form a second retinal layer underneath the host
tissue. Further, transplant of microaggregates containing clumps of few retinal
neurons from newborn mice, develop most characteristics of rod photoreceptors
including the expression of the rhodopsin and the outer segments ([32], [33]).
Unfortunately, both these type of transplantion remain isolated without inter-
acting or integrating effectively with the host retinal neurons. On the contrary,
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integration with the host retinal neurons is obtained when transplanting retinal
stem cells derived from fetal or newborn mice or rats, or from human fetuses.
In fact, when these cells are transplanted into both normal and degenerating
retinas migrate into all retina layers and develop morphological characteristics
of several retinal cell types, mainly photoreceptors ([13], [19], [46]). There is
also evidence to show that the best donor cells should be from 3 to 5 days old,
approximately two or three days after the peak of rod photoreceptor develop-
ment in the mouse retina. This suggests that, newly born rods, rather than the
stem cells, are the best candidates for cellular transplantation ([61]).
On a different rationale, promising results for RP treatment have been obtained,
still using a cell-based approach ([78]). These study have shown that injections
of hematopoietic stem cells (lineage-negative called Lin-HSCs) into the eye of
mouse models of RP (rd1 and rd10 mice) result into a dramatic rescue of both
blood vessels and photoreceptors, mainly cones. These mice show an improve-
ment of the ERG at an age when usually it is completely extinct and the rescue
effects are long lasting.
1.3.2 Implants: Subretinal and Epiretinal prostheses
The development of artificialimplants inserted in substitution of an entire part
of the pathological retina represents an active line of investigation to treat both
RP and other retinal diseases, such as macular degeneration. Advances in mi-
crotechnology have facilitated the development of a variety of prostheses that
can be connected to the brain or implanted in the eye; these implants have a
greater potential for visual restoration as they are well tolerated and remain
viable for several years; on the on the hand, retinal prostheses are only effective
where the visual pathway distal to the retinal implant is still functional. Two
types of prostheses have been developed: subretinal and epiretinal (Fig.1.8).
Subretinal prostheses contain microphotodiodes attached to micro-electrodes.
These implants, such as the articial silicon retina (5000 micro-electrodes), are
placed in the subretinal space between the outer retina and retinal pigment ep-
ithelium (Fig.1.8). The photodiodes are stimulated by light pass- ing trough
the retina, and the resulting electric current excites adjacent retinal sensory
neurons. These implants do not require an external electrical source as incident
light is sufficient for stimulation ([116]). Preclinical evaluation shows that sev-
eral species of the animal have a tolerance to the implants up to 30 months, and
histological examination does not show significant changes in the morphology
of the retina. In six patients with RP, who received a subretinal implants, vi-
sual perception but also appreciation of brightness, contrast of color, movement,
shape and vi- sual eld are improved. Some patients showed also an improvement
in visual acuity. Two major advantages of subretinal prostheses are the utiliza-
tion of existing forces between the neural retina and retinal pigment epithelium
to maintain their position and the potential of a high spatial resolution, as they
are posi- tioned close to retinal nerve cells and can stimulate neurons by means
of low electrical currents. The main disadvantages of subretinal implants include
im- paired nourishment of the inner retina due to the creation of a mechanical
barrier between the outer retina and the choroid and the occurrence of trauma
to the retina during the implanting. These prostheses also show poor dissipa-
tion of heat and therefore could damage the retina. The mechanism of action
of these implants may be by direct stimulation of retinal neurons. A specific
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neurotrophic eect elicited locally onto photoreceptors by means of the surgical
procedure cannot be excluded: a study of subretinal artificial silicon implants
in rats showed a temporary protective eect on the retina, resulting in increased
generation of photoreceptors.
Epiretinal prostheses are composed of an array of electrodes implanted on the
surface of the retina between the vitreous and inner limiting membrane. The
implants receive electrical signals from a camera positioned outside the body
(Fig.1.8); the camera transmits light signals to a microchip within the camera.
After that, the microchip decodes the signals and relays it, by wireless trans-
mission, to a microchip in the epiretinal implant that in turn stimulates the
RGCs ([116]). Clinical trials in humans have reported simple visual perception
as phosphenes; these implants have survived up to two years.
Respect to subretinal implants, an advantage of epiretinal devices is that the
camera can process signals before they reach the implant: this allows optimiza-
tion of the signal quality that leads to improved visual perception. Epiretinal
implants can also use the heat dissipating properties of the vitreous and are
therefore less likely than subretinal implants to damage the retina. The super-
cial location of the epiretinal devices reduces risk of trauma during both im-
plantation and replacement. The principal disadvantage of epiretinal implants,
compared to subretinal devices, is the complicated microtechnology and surgi-
cal techniques for a secure xation of the implant on the retina; furthermore,
the epiretinal implants requires a higher electrical current than the subretinal
implants, and these devices are being developed to generate their own currents
on stimulation ([50]).
1.3.3 Neuroprotective factors
Most mutations responsible for the RP phenotype selectively affect rod photore-
ceptors, however cones undergo degeneration secondary to the loss of rods, often
leading to total blindeness. How to save the cones has become a major research
challenge because preserving 5 % of all cones may be sufficient to maintain
a useful vision, and 50 % of cone functionality would ensure a normal visual
acuity. Treatment with neuroprotective factors, such as brain-derived (BDNF),
ciliary (CNTF), or glial cell line-derived (GDNF) neurotrophic factor, has been
found to protect partially against photoreceptors degeneration in several an-
imal models ([24], [51], [97]). Further, neuroprotective factors could work in-
dipendently of the genetic mutation that cause RP, and therefore could bypass
the very high genetic heterogeneity of this disease. CNTF, initially identified
as a factor in chick embryo extract that supported viability of embryonic chick
ciliary neurons ([2], [105]) and later purified to homogeneity, exhibits multiple
biological effects in the retina ([55], [102]). CNTF promotes the survival and
axonal regeneration of retinal ganglion cells ([108], [41], [69]) and acts as neu-
ronal differentiation factor, promotes the differentiation of cone photoreceptors
expressing green opsin in the developing chick retina ([27], [45], [111]), enhances
the expression of bipolar neuron markers in rat retinal cultures and inhibits rod
photoreceptor cell differentiation ([6], [23], [72], [92]), and promotes Muller glia
genesis from the postnatal retinal progenitor pool ([34]). It has been reported
that CNTF regulates the photodrsduction machinery of rod photoreceptor, and
the regulation was mediated through Muller cells ([109], [110]).
A recent study ([53]) shows that delivery of CNTF preservs cone cells and their
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function stimulating regeneration of COS. In the early stages of degeneration,
cone without COS are not only alive but are capable of regenerating their outer
segments (woithout COS, cones lose their light-sensig funcion), indicating that
at this time the degeneration process is reversible. They found that the delay
between loss of COS and cell death is likely in the time frame of about two
months in their animal models. Considering the rapid rod degeneration (about
10 days) in these animals, the secondary cone degeneration was relatively slow
process, which not only provides an opportunity to study the patology of sec-
ondary cone degeneration, but also serves a model for preclinical assessment of
potential treatments. Further, this finding araises the possibility that a similar
window may exist in patients with RP, in order to allow therapeutic intervention
to save cones.
The importance of rod-cone interactions for cone survival was suggested subse-
quent to the identification of the first causal mutations in RP ([22], [83]). The
rod dependence of cone survival is also supported by the experiments in vitro
([38]) and by the studies of transgenic mice and mutant zebrafish ([39], [30]),
suggesting cell-to-cell interactions in photoreceptor degeneration. RdCVF was
isolated for its effect on cone survival using embryonic chick cone cultures ([60]).
The effect of the injections of RdCVF protein from old mice 6 to 8 months indi-
cates that this factor induces cone survival directly but does not act indirectly
by stimulating rod survival, as most rods have already degenerated at the time
of treatment. This trophic effect appears indipendent from the mechanisms of
rod degenaration and thus of the causal mutation when the mutated gene is only
expressed in rods. RdCVF induces also a functional rescue, thus validating the
potential of this trophic factor for therapeutic applications, and in adressing the
secondary degeneration of cones, RdCVF administration may be used to tar-
get a pathological mechanisms common to most forms of the disease. A recent
study on the P23H rat suggests that RdCVF administration may be efficient in
the treatment of autosomal dominant RP due to rhodopsin mutations, which
account for 30-40% of cases of human autosominal dominant RP ([112]).
1.3.4 Gene therapy
Cone cell bodies remain present longer than rods in both humans and animals,
but these light-insensitive cells can be reactivated for a significant time win-
dow after the loss of photosensitivity. Another recent study ([11]) shows that
a microbial gene introduced to surviving cone cell bodies reactivated retinal
ON and OFF patways and the retinal circuitry for lateral inhibition and direc-
tional selective responses. The reactivated cones enabled RD mice to perform
visually-guided behaviors. The tested time window of intervention suggests
that persisting cone cell bodies (about 25%) was enough to induce ganglion cell
activity, even during later stages of degeneration.
1.3.5 Antioxidant agents
Another possible explanation for the slowly progressive death of cones after the
death of rods, in RP, is oxidative damage. The demostration that oxidtive dam-
age contributes to cone cell death in RP has important clinical implications. It
provides a therapeutic target that may apply to all RP patients. The enormous
genetic heterogeneity among the diseases that constitute RP is a problem for
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the development of treatments that deal with primary genetic defects. If, re-
gardless of the genetic defect that leads to rod-cell death, the same treatment
can be used to prolong cone survival and function with an enormous impact. As
long as cones survive, useful vision is possible and, although it would be ideal to
salvage rods as well, it is not necessary, because patients can carry on relatively
normal lives with only cone function.
In varius animal models, three agents, α-tocopherol, ascorbic acid, and α-lipoic
acid,have been shown to reduce one or more types of oxidative stress ([12], [98],
[73], [49], [82]), and these agents may have additive effects when used together
([100]). Another potent antioxidant that is adept at reducing oxidative damage
in mitochondria, MnTBAP, does not cross the blood-brain or blood-retinal bar-
riers under normal circumstances ([67]), but because the blood-retinal barrier
in compromised in RP, MnTBAP was also added the regimen. Daily systemic
injections of the mixture starting at P18 in rd1 mouse, the time of onset of cone
cell death, reduced staining for acrolein (marker of oxidative damage) in cones
at P35 to undetectable levels, indicating that the treatment reduced oxidative
damage in cones.
Further, an additional support for the hypothesis that oxidative stress is an im-
portant contributor to cone cell death in RP, is shown in Komeima et al. ([48]),
they found that compared to paired vehicle controls, daily administration of ei-
ther α-tocopherol or α-lipoic acid as monotherapy also reduced in a significant
increase in cone cell number at P35 in rd1 mice.
Combining this approach with other strategies designed to bolster components
of the endogenous defense system directed against oxidative stress, as well as
enhancing levels of survival factors, may be needed to provide manigful benefit
with RP.
1.4 Sphingolipids: Role in RP
Complex sphingolipids are composed of bioactive backbones (sphingoid bases
and ceramides) that can cause cell death when the amounts are elevated by
turnover of complex sphingolipids, disruption of normal sphingolipids metabolism
or induction of sphingolipid biosynthesis de novo.
Sphingolipid biosynthesis produces several bioactive intermediates formed from
complex sphingolipid turnover: ceramides, sphngoid bases ( sphingosine and
sphinganine) and sphingoid base 1-phosphates ([36]). The principal enzymes
of sphingolipid turnover are sphingomyelinase and ceramidases but there are at
least six key enzymes that partecipate in the de novo pathway that form/remove
these compounds: serine palmitoyltransferase (SPT), which catalyzes the first
reaction of the pathway; ceramide synthase, the enzyme responsible for trapping
sphinganine as dihydroceramides; dihydroceramide desaturase, which converts
dihydroceramides to ceramides; and enzymes such as sphinganine kinase, sph-
ingomyelin synthase, glucosylceramide synthase, etc. which remove or modify
these intermediates ([56]).
Ceramide, a sphingolipid metabolic precursor, is a bioactive lipid that has been
proposed to be an endogenous mediator of apoptosis; ceramide is actively in-
volved in the triggering of apoptosis in many cell systems, including neurons.
Increased intracellular levels of ceramide have been shown to occur during hy-
poxia, trophic factor removal, treatment with chemotherapeutic agents, heat,
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UV radiation, and other stress signals, such as oxidative stress ([31]). Ceramide
levels depend on the activity of several enzymes that participate in its synthesis
and catabolism. The increase in ceramide in response to apoptotic stimuli may
arise from hydrolysis of sphingomyelin due to stimulation of sphingomyelinases,
through de novo biosynthesis, or from the combined stimulation of both path-
way ([8]). In turn, several biochemical reactions lead to the disappearance of
ceramide: its hydrolysis catalyzed by ceramidases, sphingomyelin resynthesis,
or ceramide glucosylation.
Only recently, it was demonstrated for the first time that the sphingolipid path-
way is involved in photoreceptor apoptosis in Drosophila ([1]), and a mutation
in a novel ceramide kinase gene has been recently established as a cause of an
autosomal recessive form of RP, suggesting a direct link between sphingolipid-
mediated apoptosis and retinal degeneration ([104]).
1.4.1 How the Ceramide works?
The de novo synthesis of ceramide occurs in the endoplasmatic reticulum (ER)
and in mitochondria ([62], [96]). In recent years, ceramide has become increas-
ingly appreciated as a bioactive lipid that modulates apoptotic/necrotic cellular
processes that are integrated at the mitochondrial level, while sphingosine-1-
phosphate has been shown to be protective/anti-apoptotic. In fact, it has been
proposed that it is the ratio of sphingosine-1-phosphate to ceramide/sphingosine
that determines the fate of a cell ([20], [76]);
There are a number of observations that support a proapoptotic role for ce-
ramide in apoptosis:
• First, ceramide generation is a common cellular response of a variety of
cell types following exposure to apoptosis-inducing agents ([75]);
• Second, the effective doses of these agents required to induce ceramide
generation closely matches the dose required to induce apoptosis ([47]);
• Third, elevations in cellular ceramide addition in response to these agents
occurs prior to the execution phase of apoptosis ([35], [7]);
• Fourth, exogenous addition of cell-permeable ceramide analogues induces
apoptosis in a variety of cell lines ([75]);
• Fifth, ceramide-induced apoptosis is very specific, as a naturally occurring
ceramide precursor dihydroceramide does not induce apoptosis ([75]);
• Sixth, apoptosis can be inhibited upon blockage of ceramide generation
and cells that are incapable of generating ceramide are often incapable of
undergoing apoptosis ([3], [88]).
Furthermore, ceramides have been reported to have numerous effects on mito-
chondria, including enhanced generation of reactive oxygen species, alteration
of calcium homeostasis of mitochondria and ER, ATP depletion, collapse in the
inner mitochondrial membrane potential, inhibition and/or activation of the ac-
tivities of various components of the mitochondrial electron transport chain and
release of intermembrane space proteins. Further, it has been suggested that
ceramide conveys death signals to mitochondria by two principal mechanisms:
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1. ceramide leads to a selective permeabilization of the outer mitochondrial
membrane for proapoptotic proteins as a process independent of inner
membrane functions;
2. the second mechanisms presumes that loss of the permeability barrier of
the inner mitochondrial membrane is a prerequisite for the subsequent
outer membrane permebilization.
Participation of the inner mitochondrial membrane in the release of proapop-
totic preoteins involves the obligatory opening of the Permeability Transition
Pore (PTP) in the inner membrane. PTP opening occurs as a result of direct in-
teraction of ceramide with the pore in the presence of Ca2+ or that PTP opening
follows mitochondrial Ca2+ overload. Support for this mechanism arises from
experiments with many cell types in which ceramide-induced cell death is sup-
pressed by PTP inhibitors, such as cyclosporina A and bongkrekic acid ([99],
[54]). Models of mitochondrial Ca2+ overload as a consequence of ceramide-
induced Ca2+ release from ER and the direct activation of PTP by ceramides
where largely based on data obtained using artificial C2-ceramide ([74]).
1.4.2 De Novo ceramide biosynthesis enzyme and its In-
hibitor
The first demostration of toxicity owing to alteration of de novo ceramide
biosynthesis was the discovery that fumonisins inhibit ceramide synthase ([63]).
Further, it is possible that many factors that perturb intermediary metabolism
affect sphingolipid biosynthesis and thereby alter the amounts of sphinganine,
ceramide, etc. as shown in Fig.1.11. It has been shown that some aspects of the
toxicity of palmitate for cells in culture is due to sphingolipid biosynthesis and
the overexpression of Serine palmitoyltransferase (SPT) can also induce apop-
tosis ([95]). SPT is a pyridoxal 5’-phosphate-dependent enzyme that condenses
serine with palmitoyl-CoA to produce 3-ketosphinganine (Fig.1.12). For mam-
mals and yeast, two gene products (SPT1 and SPT2) are necessary for activity
and appear to be associated physically.
Because SPT is a key enzyme for the regulation of sphingolipid levels in cells,
the specific inhibitors of SPT are useful for understanding the physiological
roles of sphingolipids. Several natural and synthetic inhibitors of SPT have
been reported. ISP-1 (Myriocin) from a culture of fungus Isalia sinclairii is
a widely used and highly selective SPT inhibitor. The structure of myriocin
resembles that of sphingosine (Fig. 1.12). Myriocin inhibits ceramide synthesis
in mammalian cells with IC50 values in the nanomolar range, while a micro-
molar concentration of myriocin is necessary for the inhibition of sphingolipid
synthesis in S. cerevisiae ([70], [103]).
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Figure 1.7: This image shows the progressive degeneration of photoreceptors.
Red signal is obtained with ethidium nuclear staining; green signal represent
the inner segment of cones and the synaptic endings in the OPL, obtained with
PNA.
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Figure 1.8: Schematic representations of subretinal (A) and epiretinal electronic
implants (B): 1, camcorder mounted in a glass frame; 2, wireless transmitter;
3, extraocular junction box; 4, intraocular implants. In (C) is shown a simpli-
fied scheme of electronic epiretinal implants. From http://current.ucsc.edu/04-
05/10-18/retina.asp.
Figure 1.9: Biosynthetic and catabolic reactions for formation and removal of
the major bioactive backbones of sphingolipids.
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Figure 1.10: Schematic representation of the events that ceramide leads in cells
for the activation of the mitochondrial apoptotic pathway.
Figure 1.11: SPT1 and SPT2 are the two components of SPT. The sites of
action of commonly used inhibitors (myriocin and fumonisin) are also shown.
The subcellular locations of these reactions are indicated only for a general
context; there are likely to be other sites where some of these reactions occurs.
GlcCer, glucosyl-ceramide; Pal-CoA, palmitoyl-CoA.
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Figure 1.12: Schematic representation of the de-novo biosynthesis of ceramide
and role of SPT. The chemical structure of Myriocin, an inhibitor of SPT is
illustrated in this figure.
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Chapter 2
Materials and Methods
2.1 Animals
All the experimental procedures involving animals were carried out according to
the Italian and European guidelines for animal care (d.l. 116/92; 86/609/CE).
Animals were maintained under a 12:12h light:dark cycle. Species and strains
involved in this work include: rd10 mice (Jackson Laboratories strain B6.CXB1-
Pde6brd10/J) ([14]) and wild-type mice (Jackson Laboratories stain C57BL/6J).
2.2 Drug Delivery
The animals were treated with Myriocin, a known inhibitor of serine-palmitoil-
transferase (SPT) which is the rate-limiting factor in Ceramide de-novo synthe-
sis.
2.2.1 Acute Treatment: Intravitreal Injections
The acute treatment was obtained by means of intravitreal injections of Myri-
ocin. Rd10 mice, aged P19, were anesthetized by intraperitoneal Avertin (0.5
g/ml 2,2,2-tribromoethanol in ter-amylic alcohol; 20 µl/g body weight). Using
a glass micropipette driven by an oil Hamilton syringe, 500 nl of the solution of
Myriocin (188M, in DMSO) was injected in the vitreous body of the right eye
under a dissecting microscope, while vehicle alone was injected in the left eye.
Local antibiotics were administered to prevent infections.
2.2.2 Chronic Treatment
We performed the chronic treatment by using eye drops containing Solid Lipid
Nanoparticles (SLNs). The animals were divided in two groups. The first one
was treated with SLNs loaded with Myriocin, the second one was treated with
SLNs unloaded.
The administration of the eye drops started at P14 (the day when the animal
first opens the eyes) and ended at the different ages of the animals (P21, P24,
P27, P30, P35, P45, etc..). Eye drops were administered to each animal twice a
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day. Each administration consisted in 0.5µl for the range P14-21, and in 0.75µl
after P21.
2.2.3 Solid Lipid Nanoparticles
Solid Lipid Nanoparticles were pure lipid particles with a diameter of 40-200
nm containing a fatty acid core wrapped in a layer of phospholipids. For fea-
sibility testing, SLNs were loaded with the fluorescent dyes coumarin (Across
Organics), Nile red (Sigma-Aldrich), or N-(7-nitro-2-1,3-benzox-adiazol-4-yl)-
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (NBD-DPPE; NOF Corpo-
ration) at a concentration of 0.01-0.02% (wt/wt). For experimental testing,
SLNs were loaded with 0.15% (wt/wt) myriocin (Sigma-Aldrich). Briefly, an
oil phase composed of melted stearic acid and Epikuron 200 (96% phosphatidil-
choline; Cargill) and a water phase consisting of taurocholic acid sodium salt
(Prodotti Chimici Alimentari) and water were combined in a warm microemul-
sion. Butylated hydroxyanisole and D,L-α-tocopherol were included to prevent
oxidation.
The microemulsion was dispersed in cold water, resulting in the solidification
of nanodrops which were then washed by tangential filtration (Amicon 8010
stirred ultrafiltration cell; Millipore). SLNs preparations were sterilized by fil-
tration through a 0.2 µm filter before use.
2.3 Immunohistochemistry
2.3.1 Slice preparation
Adult mice (age ∼ 2 months) were anesthetized with an i.p. injection of Aver-
tine (15 mg/kg, Sigma-Aldrich). Eyes were enucleated and fixed by immersion
in 4% paraformaldehyde for 15 min, eyecup was dissected and maintained in
paraformaldehyde for 1 hour; washed in 0.1M phosphate-buffered saline (PBS,
pH 7.4) and cryoprotected in scalar dilution (10, 20, 30%) of sucrose. Eyecups
were then included in Tissue Tek Optimal Cutting Temperature (OCT) com-
pound (Miles incorporated, Elkhart NL) and sectioned at −20◦C into a cryo-
stat. Serial sections of 18µm in thickness were collected on glass slips coated
with gelatin (Fluka Biochemika).
2.3.2 Immunoreaction
The number of apoptotic photoreceptors for retina was assessed by morpholog-
ical methods on retinas from rd10 mice injected with Myriocin at P19 and har-
vested at P21 (17 animals). Eyes were enucleated and fixed in 4% paraformald-
heyde in 0.1M phosphate buffer. Retinas were isolated and stained with 2µM
ethidium homodimer, a fluorescent DNA-binding molecule. Whole mount reti-
nal samples were inspected with a Leica TCS-SP confocal microscope. The
outer nuclear layer, containing the nuclei of photoreceptors, was sampled at
500µm intervals along the 4 retinal meridians. Photoreceptor pycnotic nuclei,
condensed as a consequence of apoptosis, were counted in each scanned field
and the total number of pycnotic photoreceptors was calculated for each retina
with the aid of an image analyser. After the functional analysis of mice treated
with Myriocin-SLNs or unloaded-SLNs, eyes were removed, fixed for 1h in 4%
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paraformaldehyde in 0.1M PBS (pH 7.4), crioprotected by infiltration with 30%
sucrose in the same buffer and frozen at −20◦C on a cryostat stage (Leica).
Vertical sections of 14 µm were cut, collected on glass microacope slides, and
stained with ethidium homodimer 2 in order to estimate the number of sur-
viving photoreceptors by counting the rows of nuclei in the outer nuclear layer
on high-resulution images of vertical sections obtained from both central and
peripheral retinal areas ([101]).
Photoreceptor morphology and retinal histology were studied by immunocyto-
chemistry and confocal microscopy on retinal sections ([29]). Primary antibodies
used were: anti-blu/red-green cone-opsins (rbbit polyclonal, 1:1000; Chemicon),
anti-PSD95 (rabbit polyclonal, 1:500; Millipore), anti-PKC (mouse monoclonal,
1:100; Sigma Aldrich), anti-Goα (mouse monoclonal, 1:500; Sigma Aldrich). All
of the primary antbodies were revealed with secondary antibodies anti-mouse
or anti-rabbit conjugated with Alexa Fluo 488 or 568.
2.4 Western Blot Analysis
Cone-opsin proteins were assessed by semi-quantitative western blot, from both
rd10 treated and untreated mice retinas, at different ages. 60 g of protein
from each sample was electrophoresed on a 12% SDS-polyacrylamide gel. Pro-
teins were transferred to PVDF (Immobilon-P Transfer membrane 0,45 µm,
Millipore) membrane using transfer buffer (25mM Tris-HCl pH=8.3, 192mM
glycine, 20 methanol). The protein blot was blocked by exposure to 3% non-fat
dried milk and 0.1% NP-40 (Igepal, Sigma) in 20 mM Tris-HCl, 500mM NaCl
(TBS) pH=8 at room temperature for 45 minutes. After the blocking procedure,
the membrane was incubated overnight at 4◦C with primary antibodies: rab-
bit polyclonal anti-blu cone-opsin or anti-R/G cone-opsin (1:200, Santa Cruz)
diluited in blocking buffer. The reactions were revealed with HRP-conjugated
secondary antibodies (anti-rabbit IgG, 1:10000, Chemicon), incubated for 2
hours at room temperature. Bands were visualized using a chemiluminescence
kit (ECL western blotting detections agents, Amersham Biosciences, UK) and
quantified by optical density. On the same blots, cone-opsins content, were
normalized to the amounts of β-actin. The PVDF membrane was incubated
in stripping buffer (glycine 0,1M pH 2.5) for 5 minutes. Then the membrane
was washed in TBS for 6x10 minutes at room temperature. The protein blot
was exposed to the blocking medium at room temperature for 45 minutes. Af-
ter, the membrane was incubated overnight at 4C with the mouse monoclonal
anti-βactin (1:2000, Sigma) in blocking buffer. The reaction were visualized
with HRP-conjugated secondary antibodies (anti-mouse, 1:10000) for 2 hours
at room temperature.
2.5 Biochemical quantification of retinal ceramide
Basic ceramide (CER) values were assessed biochemically on retinal extracts
from rd10 and wt mice aged P14, P22 and P30 (n=6 each group). Animals
were anesthetized as above, their eyes quickly removed and the retinas iso-
lated in oxygenated ACSF medium, then frozen on dry ice for lipid extraction.
Briefly, 30 nmol of lipids, quantified as inorganic phosphate, were incubated in
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the presence of 20 µl β-octylglucoside/dioleoylphosphstidilglycerol micelles, 2
mM dithiothreitol, 6 µg of Escherichia Coli DGK (Calbiochem), 1 mM ATP,
1.3 Ci of [y32 -P] ATP (3 Ci/mol) in a final volume of 100 l at 25C for 45 min-
utes. Radioactive lipids were separated, along with reference lipid standards, by
thin layer chromatography (TLC), with chloroform/methanol/acetic acid/water
(10/4/3/2/1, by vol). Endogenous CER content was determined by the DGK
assay ([91]). Radioactive CER phosphate spots were visualized by autoradiogra-
phy, scraped and counted by liquid scintillation CER values of different animals
were averaged and referred to total phospholipids. CER was quantified also
from retinas of mice after intraocular injections of Myriocin as described above.
Left and right retinas of each animal (n=16) were isolated at P21 and processed
separately for CER biochemical assay.
2.6 Electroretinogram
2.6.1 Animal preparation
Animals were dark adapted overnight before the experimental session, mice
were anesthetized with an i.p. injection of ketamine (2.5µg/g body weight) and
xylazine (0.3µl/g body weight). A single injection was sufficient to maintain the
subject deeply anesthetized for the whole experimental session (3 to 4 hours),
as verified by the absence of corneal reflexes. Pupils were dilated with drops of
1% tropicamide (rats) or 1% atropine (mouse) (both from Sigma-Aldrich), while
constant body temperature of ∼ 37◦C was maintained by an electric thermal
blanket placed beneath the animal. A gold, ring-shaped recording electrode was
placed over each cornea, a thin layer of methylcellulose (Lacrinorm, Farmigea
Pisa) allowed the cornea to remain moist throughout the experiment. A needle
electrode inserted in the rear portion of the neck was used for ground signalling
in mice. ERG signals were amplified by a 1000x factor and filtered in the
frequency range of 0.3 - 500 Hz by a PC board amplifier (LACE elettronica,
Roma Italy), digitized at 12.8 kHz by a 16-bit DAQ board (model PCI-MIO-
16E4) driven by a custom made LabView 6.1 software (both from National
Instruments, Austin TX).
2.6.2 Light stimulation
Light stimulation protocols were generated by a 16-bit PC DAQ interface (PCI-
MIO-16E4, National Instruments, Austin TX), voltage-encoded signals were
converted into light intensity variations by a device developed in our laboratory,
described in [21]. Light stimuli were delivered into a Ganzfeld sphere of 30 cm
in diameter, with internal surface coated with highly reflective white paint, in
order to ensure an uniform illumination over the whole retinal surface.
For the flash stimulation protocol, an electronic flash unit (Sunpak B3600 DX
, Tocad Ltd. Tokyo JP) delivered flashes of white light, whose energy decayed
with a τ = 1.7 ms and whose scotopic efficacy was estimated following [59]. The
estimated retinal illuminance was 5.7× 105 Φ (Photoisomerization per rod) per
flash. The whole spectrum of light intensities were achieved by placing optical
neutral density filters within the light path. The luminance was expressed as a
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function of time by the equation(2.1):
L(t) = L0 (1 +m · sin (ωt))
= L0 (1 +m · sin (2piνt)) (2.1)
where: L0 is the mean luminance, estimated to be ∼ 40 φ; m is the contrast
value, allowed to assume values from 0 to 1, a constant value of 0.85 was used
during all the experiments; ν is the frequency of the generated sinusoid, varying
from 0.3 Hz to 30 Hz within each trial.
Estimations of light intensity impinging on the rodent retina were carried out
according to [58] using the equations (2.2) (2.3).
F(λ) =
I
Ephoton
=
I
h · cλ
(2.2)
where: F(λ) is the photon density [photons m−2 s−1]; I is the measured irra-
diance [W m−2]; h is the Planck constant (6.6626 × 10−34 J sec−1); c is the
light’s speed in a vacuum (2.99792× 108 m s−1) and λ is the wavelength of the
light [m].
Φ
∆t
= F(λ) · τ(λ) · ac(λ) · Spupil
Sretina
(2.3)
where: Φ∆t is the estimated photoisomerization per rod per second delivered
to the retina; F(λ) is the photon density; τ(λ) is the transmission of the pre-
photoreceptor ocular media (estimated as 0.7 for both rats and mice); ac(λ) is
the “end-on collecting area” of rod photoreceptors (1.3 µm2 for rats, 0.87 µm2
for mice); Spupil is the area of the fully dilated pupil (7.1 µm2 for rats, 3.2 µm2
for mice); Sretina is the area of the retinal tissue (55 µm2 for rats, 18 µm2 for
mice).
2.6.3 ERG protocols
Mice were subjected at two different ERG protocols: scotopic and photopic
ERG. The responses to the brightest flashes, of the scotopic ERG, include mixed
rod and cone components patway, whereas in photopic ERG the response gen-
erate only from the cone patway. In scotopic ERG, mice were subjected to six
different flash intensities, each repeated five times, with an interstimulus inter-
val that ranged from 60s for dim light to 5 min for the brightest flashes. Five
ERG traces at each flash luminance were averaged before measurements of a-
and b-wave amplitudes. The amplitude of the a-wave was taken as the different
between baseline and the lowest value, whereas the amplitude of the b-wave was
measured from the trough of the a-wave to the peak of the b-wave.
Isolated cone components were obtained by superimposing test flashes on a
background of saturating intensity for rods (30 cd*s/m2).
From the ERG responses obtained by photopic stimulation we analyser the
Oscillatory Potentials (OPs) ([52], [114]). OPs are specific components of elec-
troretinograms and consist of a series of wavelets embedded in the ascending
limb of the ERG b-wave. Analyze the OPs is a method in order to understand
the functionality of the inner retina, in fact OPs are generated from the inner
retina, presumably amacrine cells and adjacent retinal neuron network ([106]).
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Chapter 3
Results
3.1 Retinal content of Ceramide
To evaluate if, in the rd10 mouse, there are altered levels of retinal ceramide,
retinas were obtained from both rd10 and wt pups between P12 and P30. Total
retinal ceramide, normalized to the amount of inorganic phospate (Pi) from
total phospholipid, was similar in the two grups until P16; A P21, time of peak
of rods degeneration, the levels of ceramide was significantly increased in rd10
retinas respect to wt retinas (3.1). Note that after P16 in rd10 retinas the levels
of ceramide increase while in wt retinas the ceramide content starts to decrease.
Figure 3.1: Time course of endogenous ceramide content in retinas of litter-
maters during the first month of life: in rd10 retinas a significantly increase of
the ceramide levels is in concomitance with the peak of retinal degeneration (*
P=0.05 t test;** P=0.001 t test)
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3.2 Pharmacological effects on Retinal Ceramide
levels and rod-photoreceptors survival
3.2.1 Acute Treatment
In order to evaluate whether the high levels of ceramide in phatological condi-
tions were reduced by a pharmacological treatment, we administered Myriocin,
an inhibitor of the biosynthesis of ceramide. Miryocin was administered by
intraocular injection on P19 mice followed by ceramide quantification on P21.
Myriocin injection into the right vitreous body reduced the retinal ceramide
levels with respect to the left eye which was injected with the vehicle alone.
The results show that this treatment was effective in bringing ceramide to levels
considered normal for P21 mice (3.2).
Figure 3.2: Effect of intraocular injection of Myriocin on retinal ceramide con-
tent in rd10 mice. In 14 of 16 animals, Myriocin lowered ceramide content; Myri-
ocin induced a 25.4% reduction in mean ceramide content, from 4.09 pmol/nmol
Pi to 3.05 pmol/nmol Pi (SD=0.97) (P=0.011, paired t test)
The protective effect of a single injection of Myriocin on photoreceptors survival
was investigated by both counting the number of apoptotic photoreceptors and
recording the scotopic ERG, in retinas from treated and untreated-eyes. Iso-
lated retinas were stained with a fluorescent nuclear dye to identify pycnotic
nuclei (condensed DNA, cell start to die by apoptotic process) and visualized
by confocal microscopy. Retinas from treated-eyes had fewer intensely stained
nuclei than untreated-eyes (3.3). Qunatitative analysis shows that a single injec-
tion of Myriocin was effective in reduced the number of pycnotic photoreceptors
(reduced by 52.6%).
The scotopic ERG was recorded from P21 animals after two days after injec-
tion the treatment with injection of myriocin (right eye) and vehicle alone (left
eye). The scotopic ERG response to flashes of light of different intensities was
27
measured in dark adapted animals (3.4). Surprisingly, no significant difference
could be detected in the ERGs of eyes injected with myriocin (red bar) or with
the DMSO vehicle (black bar) (3.5).
Figure 3.3: Fluorescence microscopy of retina whole mount after a single injec-
tion of Myriocin. Retinas, from myriocin treated eye (A) and vehicle treated
eye (B), were fixed and stained with ethidium homodimer. Quantification of
pycnotic nuclei (C), myriocin injection was associated with a reduction in the
number of pycnotic photoreceptor nuclei on P21 (** P=0.007, t test)
In order to evaluate if a single injection of myriocin was not sufficient to induce
a recovery in retinal fuctional we performed a chronic treatment with myriocin.
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Figure 3.4: Example of ERG responses at different intensity of light. The red
tracks represent the treated eye with myriocin and the black tacks represent the
treated eye with DMSO (vehicle). A single intraocular injection of Myriocin did
not have significant protective effects on retinal function, as shown by similar
amplitudes and kinetics of a and b-waves in the two experimental conditions
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Figure 3.5: Average of eleven treated and untreated eyes. Treatment with a
single injection with myriocin didn’t induce significant change in both a-wave
and b-wave
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3.2.2 Chronic Treatment
The first chronic treatment was performed by instilling, once daily, eye drops
of a solution of myriocin (1µl of 3.77 mM solution in DMSO) to the cornea
of rd0 mice once daily for 4 days. Microscopic analysis for pycnotic nuclei and
ceramide quentification revealed no significant difference between myriocin- and
DMSO-treated eyes, suggesting that possibly the drug could not cross the ex-
ternal tissue of the eye thus failing to reach the retinal terget.
We therefore turned to a different strategy, based on the use of solid lipid
nanoparticles (SLNs), that could enable the drug to diffuse across the ocular
tissue. We first investigated whether SLNs pure lipid particles with a diameter
of 40-200nm labeled with a fluorescent dye, instilled into the conjuntival sac,
could reach the retinal layers ([101]) in wt mice and showed by confocal mi-
croscopy the presence of bright aggregates in the outer nuclear layer (ONL) and
also between photoreceptors and retinal pigment epithelium ([101]).
SLNs were subsequently loaded with myriocin. The concentration of the drug
in different preparations was between 0,4 and 1.0 mM.
First of all, a eye drop solution containing the Myriocin-SLNs was administered
to wt mice starting on P14 upto P24. Wt mice included two distinct groups:
treated (Myr-SLNs) and control (Vehicle-SLNs) groups. After the treatment
sample of retinas from treated mice were collected to evaluate by morphological
analysis ([101]), possible adverse effects onthe retinal structure. Other animals
from same group were used to evauate the functional performance of the retina
by measuring the ERG response (3.6). Subsequently we turned to the treat-
ment with myriocin of rd10 mice. The protocol of the daily eye drop treatment
of transgenic mice sterted on P14 to end at different ages (P21, P24, P30,
P35) in various animal groups. From P21 to P35, different animals underwent
ERG testing of retinal function followed by retinal microscopic analysis (3.7).
In both control and myriocin-treated rd10 mice, mean aplitude of the b-waves
and a-waves decreased progressively over time in concomitance with retinal de-
generation. However, the b-wave amplitude of myriocin treated animals was
substantially higher than that recorded from control animals at all time execept
P35. Significant diffrences were observed, between the two groups, in the am-
plitude of a-wave at P30 and P35 (3.8).
Also, microscopic analysis of vertical section of treated and untreaed retinas,
revealed a protective effect of myriocin on the number of photoreceptor rows
(3.9); further, the morphology of surviving photoreceptors was preserved as well
as dentrites in rod bipolar cell ([101]).
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Figure 3.6: Lack of functional effects of myriocin on wild-type mouse retinas.
The upper panel represents ERG traces obtained from a wild type mouse after
prolonged administration of myriocin-SLNs. The bottom panel is the average
of six treated and untreated mice. Treatment with myriocin didn’t induce sig-
nificant changes in both a-wave and b-wave amplitudes
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Figure 3.7: Morphological and functional effects in the P24 rd10 retinas af-
ter chronic treatment with Myriocin-SLNs. (A) Confocal analysis of treated
and untreated rd10 mice. The number of photoreceptor rows was increas in
Myriocin-SLNs retinas respect to vehicle-SLNs one. (B) ERG responses ob-
tained from the same animals at different intensity of flashes light
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Figure 3.8: Amplitude of ERG a and b-waves from eyes of rd10 mice treated
with control SLNs or myriocin SLNs from P14 and exposed to light flash of 5.1
cd*s/m2. The insert represents an example of ERG recording at P30.
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Figure 3.9: Quantification of photoreceptor rows at P24 and P30 in the rd10
mice treated with control SLNs or myriocin-SLNs (* P=0.002, ** P=0.003 t
test)
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3.3 Morphological and functional evaluation of
the retina in the later stages of RP in rd10
mice
RP is mainly caused by mutations in rod-photoreceptors specific genes, but in
the later stages also cone-photoreceptors, whose genes are not affected, start
to die. In this study we analyzed the cone photoreceptors functional status
respect to wt mice. We used scotopic and photopic ERG in rd10 mice aged
P20. At this stage of the animal life only the rod-photoreceptors are facing the
apoptosis process that leads to their eventual loss. It seems therefore reasonable
to assume that cones functional performance were similar to that of wt. The
results illustrated in (3.10 A) confirm the prediction that the rod-driven ERG
response amplitude is smaller in the rd10 P20 mice than in wt ([29]) and that
both response amplitude and sensitivity of the cone pathway in rd10 and wt
mice is similar 3.10 B.
Further, analysis of the kinetics if the ERG response reported in figure 3.11
shows that responses from both rods and cones are significantly slower in rd10
that in wt mice([29]). This result indicates that in the early stages of RP, also
cone photoreceptors reveal symptoms of functional damage(3.11).
It is well known that in RP patients the residual vision is based on cones that
survive longer than rods, but with time also cones are doomed to death. The
present results show that despite a longer survival also cones show signs of
damage at already early stages of retinal degeneration.
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Figure 3.10: In this figure the red plot represents the response obtained mainly
from rod patway and the green plot represents the ERG responses obtained
from cone patway
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Figure 3.11: Peak time obtained from rod patway (red) and cone patway (green).
Note that in both panels the peak of the responses in rd10 mice is slower than
wt mice (** P=0.002 t test)
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3.3.1 Time-course of cone-photoreceptors function in rd10
mice
In order to evaluate the cone-photoreceptors function we measured photopic-
ERG in rd10 mice at different ages (3.12). Animals were light-adapted with a
steady background wich saturated the rod-photoreceptors, after that a bright
flash stimulated the cone responses. The cone b-wave amplitude in rd10 mice
at P20 was about 279.6 µV (SD 40.2 µV) (3.12 B). This result shows that, in
the early stages of RP, as far as the response amplitude is considered, cone-
photoreceptors produce seemingly normal responses to light. Furthermore, as
shown in fig. 3.12 (A) also the light sensitivity of cone-photoreceptors in rd10
P20 mice was normal. However, starting from P30 both sensibility and ampli-
tude of rd10 mice started to decrease (3.12). By the time, cone-photoreceptors
start to die, rods are nearly copletely lost. A massive loss of function of the
cone-photoreceptor at around starts P40.
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Figure 3.12: (A) Average of b-wave amplitude at different intensity of flash
light superimposed on steady background. (B) Time-course of the cone-
photoreceptors activity in rd10 mice. In the early stages of the patology the
cone b-wave in rd10 was the same of wt mice; On P30 the cone b-wave starts to
decrease and from P40 up to P60 the amplitude of b-wave was stably lowered
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3.3.2 Myriocin effects on cone-photoreceptors survival
There is a large consensus on the notion that death of cones is a consequence
of the loss of rods ([71], [89]). Up to now, however, no evidence is available
to explain the process that may cause of the secondary degeneration of cones.
Regardless of the mechanism that causes the death of cones, following the rod
loss it seems reasonable to predict that prolonging the rods survival by reduc-
ing the levels of ceramide may prove beneficial also to cones. The rationale for
this proposition may be dual: a) the hypothesized dependence of cone survival
from the rod integrity, b) a direct effect on cone of the reduced levels of an
apoptotic agent. These possibilities were then tested by analyzing the effects of
Myriocin chronic treatment on fuctional, biochemical and morphological tests
of cone photoreceptor cells integrity.
In this study the treatment of rd10 mice started at P14 and extended up to P20,
P30, P40, P50 and P60 respectively. Cone ERG response amplitude and kinet-
ics, (3.13, 3.14) as well as sensitivity were shown to improve following chronic
treatmen with myriocin at P40 and P60. The effects of myriocin treatment was
also confirmed by western blot analysis for cone-opsin protein (3.15).
Figure 3.13: Photopic ERG recording from rd10 mice at different ages. The
green plot represents the responses of the animals groups treated with Myriocin-
SLNs, the black plot represents the responses from animal groups treated with
vehicle-SLNs. The improvement of the cone b-wave amplitude was significantly
on P40 and P60 rd10 mice
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Figure 3.14: Average of b-wave amplitude from cone-photoreceptors patway.
Bars in gray scale represents groups treated with vehicle-SLNs, while bars in
green scale represents groups treated with Myriocin-SLNs. The treatment with
myriocin tends to improve the cones features at each time point; at P40 and
P60 the cones b-wave amplitude was significantly increased (* P=0.05 t test)
in myriocin treated animals respect to control animals
Figure 3.15: Western Blot analysis performed after myriocin treatment. For the
semi-quantitative western blot analysis, the four lines were loaded with retinal
homogenates (60µg of total protein); cone-opsin content in the myriocin-SLNs
treated retinas was higher than vehicle-SLNs treated retinas
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In order to understanding the status of the photoreceptors synapses to bipo-
lar cells, we analyzed the morphological feature by using confocal microscopy
(3.16, 3.17, 3.18). The confocal microscopy analysis showed that in the myriocin
treated retinas the layer structure was more conserved than in untreated retinas.
In rd10 P40 treated retinas the status of retinal layers were improve respect to
untreated retinas (fig. 3.16). In fig. 3.17 the red staining represents the PKC
protein, a specific marker for the rod-bipolar cells; green staining represents the
PSD95 protein, a specific marker for both rod and cone pre-synaptic terminals.
This image shows that in myriocin-treated retinas, the dendritic terminals were
present in corrispondece to PSD95 while in vehicle treated retinas the bipolar
cells were completely bare. This observation suggests that in myrocin treated
retinas the synaptic connectivity is maintained. Possibily, prolonging the sur-
vival of photoreceptors facilitates the formations of ectopic synapses from cone-
photoreceptors to rod-bipolar cells ([87]). Further, fig. 3.18 shows that, also
in retinas from rd10 P60 mice, cone-photoreceptors are most intact in treated
mouse respect to untreated one.
Figure 3.16: Confocal microscopy analysis from both treated and untreated
retinas in P40 mice. The green staining, in the upper panels, was obtained with
antibody anti-cone opsins blu and red/green while in bottom panels, the green
staining was obtained with an antibody anti-Goα. In the upper myriocin-SLNs
treated retinas the arrows indicates the inner segment, body cell and synaptic
terminal of cone-photoreceptors; in bottom treated retina the arrows indicate
the dendritic terminals and bodies of ON bipolar cells
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Figure 3.17: Confocal microscopy analysis from both treated and untreated
retinas in P60 mice. The red staining was obtained with antibody anti-PKC
and the green staining was obtained with antibody anti-PSD95. In the myriocin-
SLNs treated retinas the arrows indicates the dendritic terminals
Figure 3.18: Confocal microscopy analysis from both treated and untreated
retinas in P60 mice. The green staining was obtained with antibody anti-cone
opsins blu and red/green. In the myriocin-SLNs treated retinas the arrows
indicates the cone-photoreceptors
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3.3.3 Myriocin effects on inner retina
Furthermore, we analyzed the Oscillatory Potentials (OPs) from the photopic
ERG responses. The OPs are generated at the inner retinal mainly the amacrine
cells. Amacrine cells have animportant role in retinal processing eithin the inner
retinal layerwere they connect withboth bipolar and ganglion cells. Understand-
ing their performance is crucial to assess the viability of the inner retina.
First of all, we established the suitable intensity of light for this analysis, and
observed that in the late stages of RP the OPs amplitude and frequency de-
creased, mainly in untreated mice while in myriocin treated retina they were
similar to the control wt (3.19). Further, we estimated the area subtended by
Figure 3.19: OPs from cones photopic ERG responses. The left panel (gray
scale) represents the time course of OPs in untreated rd10 retina. The right
panel (green scale) represents the same time course in myriocin treated rd10
mice. The OPs amplitude and frequency were improved in treated retinas
the OPs by calculating the integral curve (3.20 A). The results are illustrated in
fig. 3.20 B were it is seen that the total OPs area at P60 is significantly larger
in myriocin treated retinas.
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Figure 3.20: Panel A shows an example of curve obtained from OPs analysis;
the area under the curve rapresents the total OPs amplitude. The plot bars in
the panel B represent the average of four an five animals respectively in control
and treated groups. Note that the OPs total area was significantly increased in
myriocin treated animals, indicating an improvement in the functional perfor-
mance of inner retina neurons
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Chapter 4
Discussion
4.1 Effects of Myriocin treatment in the early
stage of RP
This study demonstrated for the first time that, in the rd10 mouse model of
RP, the level of retinal ceramide starts to increase from the third week of life,
during the same period of maximum photoreceptor loss, whereas in wild-type
mice ceramide levels progressively decrease. Single intraocular injections of
myriocin, a selective inhibitor of SPT, the rate-limiting enzyme of ceramide
biosynthesis, decreased retinal ceramide and reduced the number of apoptotic
photoreceptors in the short term. Functional benefits of myriocin became ap-
parent after prolonged daily treatment, with the ceramide inhibitor caged in
solid lipid nanoparticles, non invasively administered as eyedrops. In rd10 mice
treated with myriocin-SLNs for 10-20 d, the death of visual cells was slowed,
their morphology preserved, and the overall retinal degeneration delayed.
The finding that ceramide levels increase in the rd10 mouse in temporal associ-
ation with the process of photoreceptors demise provides biochemical evidences
that this sphingolipids is involved in the neurodegenerative process of RP ([5],
[29]). This results is therefore in accordance with the notion derived from genetic
studies that human autosomal recessive RP can be caused by loss-of-function
mutations in CERKL, an enzyme that lowers ceramide content by phosphory-
lation ([4]). The results are also consistent with the increased ceramide levels of
other forms ofdystrophy, such as Alzheimer’s disease were the cell death occurs
by apoptosis ([37]).
In a previous study conducted on a Drosophila models of RP ([1]), the increased
retinal levels of ceramide were lowered by genetic manipulation, while in this
study ceramide levels were lowered pharmacologically. Because a non invasive
pharmacological approach is more easily achieved in humans than gene therapy,
in the long run, the strategy proposed here might become applicable to humans
in the long run.
A functional benefit of myriocin was observed only after prolonged treatment
but not after a single intraocular injection, despite the fact that both admin-
istration methods reduced ceramide levels. The lack of measurable functional
effects of single myriocin administration might be ascribed to the small propor-
tion of photoreceptors rescued from apoptotic death in short period of study (2
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d). Possibly the corrisponding effect on the ERG fell below the sensitivity of
this functional test.
This study has a few limitations, the most evident being that chronic adminis-
tration of myriocin rescued a fraction of photoreceptors for a limited period of
time, moslty delaying the inevitable death process in these cells. However, it
has to be considered that prolonging the natural evolution of a disease like RP,
which characteristically exhibits a slow progression, can nontheless represent for
patients an important advantage. Another limitation is that we studied a single
mutations that leads to RP, whereas it is known that this disease is genetically
heterogeneous ([64]).
Overall, the results described here are particularly encouraging, considering that
the partial loss-of-function rd10 mutation mimics typical RP forms with mod-
erately aggressive phenotype and good retention of retinal architecture ( [29]).
These are features that portray human RP patients as likely canididates for gene
therapy, in which the defective gene is replaced by a functioning one by means
of genetically engineered viral vectors. A protective pharmacological approach,
based on the non-invasive administration of SPT inhibitors, could prolong the
lifespan of photoreceptors in recessive form of RP, pending gene therapy at a
later stage. SPT inhibitors similar to myriocin could therefore contribute to
enlarge the panel of bioactive substances already used as neuroprotectants to
delay photoreceptors death in this disease ([48], [97]).
Finally, the particular advantages of the SLNs used here are their lack of unde-
sirable effects and their suitability for carrying nonpolar, lipophilic compounds.
These features can be exploited for drug delivery in retinal disorders other than
RP.
In conclusion, the first step of this study demonstrates that pharmacological
targeting of ceramide biosynthesis has the potential to slow the progression of
RP in a mammalian models and therefore may represent a therapeutic approach
to treating this disease in humans.
Furthermore, considering that an increment in the rate of rod survival is known
to promote a proportionally longer viability of cones, essential for daylight
vision, it is possible that the beneficial effects of delaying the sphingolipid-
mediated rod demise would propagate to cones as well.
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4.2 Effects of Myriocin treatment in the later
stage of RP
In the rd10 model of retinal degeneration the loss of rod visual cells, in untreated
mice, is nearly complete at around P40. At this stage animals may only relay on
cone vision that is usually maintained up to no later than P80. Although cone’s
survival extends well beyond rod’s survival, our data show, nonetheless, that
signs of functional damage can be detected in cones at the very early stage of
rod degeneration. Interestingly, the functional impairment of cones occurs when
the structure of these cells is still seemingly normal. Treatment with myriocin
rescues rods and also protects cones by partially preventing their functional
damage and by significantly prolonging their survival. These observation have
important practical consequences because an extension in time of cone viability
may be crucial for the applicability and success of some of the most recent
therapeutic approaches, and above all, the halorhodopsin-based therapy ([11]).
In rd10 mice as well as in a number of other genetic defects identified in animal’s
and human’s RP the cause of cone degeneration still remains an open question.
The main difficulty in understanding this occurrence is that the genetic damage
that affects rods seems to spare cones. The prevailing hypothesis in this regard
is that cones, to survive, require the presence of rods whose protective action
would be exrted through the release of some, not yet indentified, diffusibile
factor. In principle this would explain why prolonging rod survival by myriocin
also extend cone viability. It must be pointed out, however, that this should
not be taken, by all means, as a ruling out of the possibility of a direct action
of the drug also on cones. The notion of a direct action of myriocin on cones
is supported by the observation that the functional damage, observed in these
visual cells at the earliest stages of rod degeneration, may be to some extent
reverted by myriocin. The fact that a fuctional damage is already present in
cones when rods are still viable arises a number of interesting possibilities. If we
assume that rods protect cones by releasing trophic factors, the present results
indicate that this action fails as rods start degenerating possibly because the
genetic damage also impairs their ability to produce or release the protective
molecule. Another possibility is that a subtle as yet undisclosed genetic damage
also affects cones.
The cone involvement in retinal degeneration is also puzzling for other reasons.
We have shown that the early functional damage of cones in untreated rd10
mice is reflected in the flash ERG where both amplitude and kinetics of the
light response are affected. The treatment of these animals with myriocin is
effective in restoring the response amplitude near to normal levels, but fails
to correct the altered kinetics. It is perhaps important to note that the sole
correction of the amplitude does succeed in extending he cone survival but they
remain doomed to death and the eventual shedding at the latest stage of retinal
degeneration is a warning that protection was not complete, as possibly reflected
by the inability of myriocin to also correct the kinetics of the light response.
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